Last reviewed · How we verify
HCP1202
HCP1202 is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss.
HCP1202 is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | HCP1202 |
|---|---|
| Also known as | HCP1202 Capsule |
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Drug class | GLP-1/GIP receptor agonist |
| Target | GLP-1R, GIPR |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By simultaneously activating GLP-1 and GIP receptors, HCP1202 enhances insulin secretion in response to glucose, slows gastric emptying, and increases satiety signaling in the brain. This dual mechanism produces greater improvements in blood glucose control and body weight reduction compared to single GLP-1 agonists, with a favorable safety profile in early clinical development.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Gastrointestinal disorders
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |